metaEvidence - overview

button bars forest bayes pooled summary circles


			deaths (OS)
es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)
es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)
versus lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
	trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel vs. lapatinib plus epirubicin and cyclophosphamide followed by docetaxel	1	-
la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)
versus trastuzumab
	pertuzumab plus trastuzumab vs. trastuzumab	1	-
versus trastuzumab plus chemotherapy
	trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy	1	0.82 [0.65; 1.04], 1 RCT, I2=0% inconclusive result
versus trastuzumab plus docetaxel
	pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel	2	0.66 [0.52; 0.84], 1 RCT, I2=0% conclusive unassessable degree of certainty
la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)
versus lapatinib plus capecitabine
	neratinib plus capecitabine vs. lapatinib plus capecitabine	2	0.88 [0.74; 1.06], 2 RCTs, I2=0% inconclusive result
versus placebo
	neratinib vs. placebo	1	-
versus trastuzumab plus capecitabine
	tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine	2	0.66 [0.50; 0.88], 1 RCT, I2=0% conclusive unassessable degree of certainty